Monday December 20, 1999

COMPANY PRESS RELEASE

Transgenomic Achieves Milestone

Transgenomic, Inc. announced today that the Company has surpassed 200 Wave® Nucleic Acid Fragment Analysis Systems sold and placed. The installations have occurred worldwide, with sales in twenty countries.

"This is a momentous achievement for our Company as we strive to play a key role in the advancement of genetic research and disease discovery," said Collin D'Silva, Chief Executive Officer. "very powerful that our technology is being accepted as a standard in DNA fragment analysis by the scientific community. With our growing list of customers and collaborative efforts, we are well positioned for continued excellent growth as we enter the new millennium," D'Silva went on to say.

Certain statements made by Transgenomic, Inc. in this press release may be forward looking. These may be identified by the use of forward-looking words or phrases such as in the following examples: "anticipate," "believe," "estimated," "think," "planned," "potential," "should," others. Any forward-looking statements are based on the Company's current expectations. The Company undertakes no obligation to publicly release the results of any revisions to any forward looking statement, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Statements in this release should be evaluated in light of these important factors.

For more information contact investorrelations@transgenomic.com.